Antengene (6996) Stock Overview
A clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
6996 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Antengene Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.09 |
| 52 Week High | HK$8.16 |
| 52 Week Low | HK$2.76 |
| Beta | 0.36 |
| 1 Month Change | 20.29% |
| 3 Month Change | -30.09% |
| 1 Year Change | -8.50% |
| 3 Year Change | 192.14% |
| 5 Year Change | -75.80% |
| Change since IPO | -77.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6996 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -4.2% | -0.9% | 0.3% |
| 1Y | -8.5% | -21.2% | -3.9% |
Return vs Industry: 6996 exceeded the Hong Kong Pharmaceuticals industry which returned -21.2% over the past year.
Return vs Market: 6996 underperformed the Hong Kong Market which returned -3.9% over the past year.
Price Volatility
| 6996 volatility | |
|---|---|
| 6996 Average Weekly Movement | 9.6% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 7.6% |
| 10% most volatile stocks in HK Market | 16.3% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 6996 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6996's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 129 | Jay Mei | www.antengene.com |
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor for the treatment of cervical cancer and other advanced solid tumors.
Antengene Corporation Limited Fundamentals Summary
| 6996 fundamental statistics | |
|---|---|
| Market cap | HK$2.78b |
| Earnings (TTM) | -HK$276.68m |
| Revenue (TTM) | HK$121.88m |
Is 6996 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6996 income statement (TTM) | |
|---|---|
| Revenue | CN¥105.34m |
| Cost of Revenue | CN¥18.51m |
| Gross Profit | CN¥86.83m |
| Other Expenses | CN¥325.96m |
| Earnings | -CN¥239.13m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 82.43% |
| Net Profit Margin | -227.01% |
| Debt/Equity Ratio | 39.1% |
How did 6996 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/19 06:04 |
| End of Day Share Price | 2026/07/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Antengene Corporation Limited is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyu He | China International Capital Corporation Limited |
| Wangbin Zhou | Citigroup Inc |
| null null | CMB International Securities Limited |